BOARD OF DIRECTORS

Frank L. Douglas, M.D., Ph.D. has served on NitroMed’s our board of directors since April 2005.  

Dr. Douglas is recognized for his leadership and involvement at the Massachusetts Institute of Technology (MIT), where he was active until his departure in July 2007.  He established and led the Center for Biomedical Innovation Management at MIT, was a Professor of Practice for the MIT School of Engineering, the MIT Sloan School of Management, the MIT School of Science and the Harvard-MIT Division of Health Sciences and Technology.
From 1992 until his corporate retirement in 2004, Dr. Douglas held key management roles with several global pharmaceutical companies, including; Executive Vice President, Drug Innovation and Approval, and Chief Scientific Officer for Aventis Pharma AG (1999-2004), Executive Vice President and Head of Global Research and Development at Hoechst Marion Roussel (1995-1999) which merged with Rhone Poulenc Rorer to from Aventis S.A., and Executive Vice President of Global Research & Development for Marion Merrell Dow (1992-1995).   Over this span of 22 years in the pharmaceutical industry, Dr. Douglas led the discovery, development, and market introduction and life cycle management of more than 20 drugs, including Allegra, Actonel, Anzemet, Taxotere, Lantus and Exubera.

Dr. Douglas graduated cum laude from Lehigh University , and earned his Ph.D. in Physical Chemistry and an M.D. from Cornell University .  He completed his internship and residency in internal medicine at the Johns Hopkins Medical Institution and a fellowship in neuroendocrinology at the National Institutes of Health.  Dr. Douglas is a Fellow of the High Blood Pressure Council, and sits on the Board of Trustees at Lehigh University and the University of Frankfurt/Main , Germany . 

Dr. Douglas currently serves as Chairman of the Board of Directors for Altanos Pharmaceuticals Holding, Inc., and is also a director at Gene Logic, Inc..